Business Wire

IPROOV

20.4.2021 07:02:11 CEST | Business Wire | Press release

Share
iProov Face Verification Selected by itsme® to Support Global Expansion

British company iProov has today announced that European digital identity leader, itsme®, has selected iProov’s Genuine Presence Assurance® technology to support its global expansion.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210419006005/en/

Launched in 2017 by qualified trust service provider, Belgian Mobile ID, itsme® is Belgium's digital identity app. It is currently used by more than 35% of the Belgian population and is relied on by more than 150 companies in the private sector (banks, insurance companies etc) and by the Belgian government. From now, users in the Netherlands will also have access to itsme®’s trusted ID solution and will be able to securely authenticate themselves and onboard to digital services. iProov will verify the faces of new users, whatever their mobile device.

“We needed a technology partner to support our mission to make secure digital identities available to everyone. iProov was the obvious choice. They hold privacy and security in the highest regard and offer the future-proof, cutting-edge technology that will enable us to identify users internationally,” Stephanie De Bruyne, CEO at itsme, said.

Onboarding for an eIDAS level high or qualified signature has to meet very demanding, independently audited and certified international standards. Previously, these could only be met by an in-person meeting or video calling. itsme® avoids these expensive and tedious methods by using iProov’s faster, more convenient, less costly and more secure solution.

iProov’s Genuine Presence Assurance technology enables users to onboard to the itsme® service in a way that is both secure and effortless to use. A user scans their identity document using their mobile device. They then scan their face in a process that takes a few brief seconds. iProov technology ensures that the user is the right person, matching the identity in the document, that they are a real person, and that they are authenticating right now. The iProov process maximizes inclusiveness by eliminating the need for users to follow instructions to move or read out words.

Andrew Bud, Founder and CEO of iProov, said: “We are delighted to be working with itsme®, a true pioneer in the provision of digital identity trust services. I have huge respect for how itsme® has successfully driven the uptake of digital identity in Belgium, so it’s a pleasure and privilege to be partnering on a solution for the Netherlands. This is yet another demonstration that iProov is the technology of choice for Europe’s leading eIDAS providers.”

itsme® enables identification, secure onboarding, authentication on website or app, confirmation of transactions and qualified electronic signatures, all to the highest level of security. itsme® was granted accreditation by the Belgian government as an official form of digital identity in 2018 and on a European level in 2019 (LOA high eIDAS).

About iProov

Founded in 2012, iProov is the world leader in online facial biometric authentication, working with governments, banks and other enterprises to securely verify customer identity. Used for effortless onboarding and authentication, customers include the U.S. Department of Homeland Security, the UK Home Office, the UK National Health Service (NHS), the Australian Taxation Office, GovTech Singapore, Rabobank, ING, and others. iProov’s technologies include Liveness Assurance™ and Genuine Presence Assurance®, which ensures that an online customer is the right person, a real person, and is authenticating right now. This protects against spoof attacks from photos, videos, masks and digital injection attacks and the emerging threat of deepfakes. iProov was recognized as a Gartner Cool Vendor 2020 in Identity Access Management & Fraud Detection. For more information, please see www.iproov.com or follow us on LinkedIn or Twitter.

About itsme®

Since its launch in 2017, the itsme® app has become the widely accepted simple and secure standard for mobile identification and the protection of privacy in the digital world. itsme® enables the following: identification (creating a new online account and sharing identity details), authentication (secure, personal access to a website or application), confirmation of a transaction (approval of an order or bank payment) and, finally, the legally binding electronic signing of documents (qualified electronic signature with the highest level of security). itsme® was granted accreditation by the Belgian government as an official form of digital identity in January 2018 and on a European level in December 2019 (LOA high eIDAS). The itsme® app is used extensively in the financial sector among others because it complies with PSD2, FATF and GDPR guidelines. It has also been awarded ISO27001 certification.

itsme® was developed by the Belgian Mobile ID consortium, which combines the seven Belgian market leaders from the banking and telecommunications sectors: Belfius, BNP Paribas Fortis, CBC/KBC & ING, on the one hand, and Orange Belgium, Proximus and Telenet on the other. itsme® takes the security of the electronic identity card to the world of mobile.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye